Could a Ketamine-Like drug improve sedation for sepsis patients on life support?

NCT ID NCT07556172

Ongoing Disease control Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests esketamine, a drug related to ketamine, for sedation and delirium prevention in 80 septic patients who need a breathing tube. The goal is to see if esketamine can reduce time on the ventilator and improve survival compared to standard sedatives. The trial is active but no longer recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Esketamine
What this could lead to: If successful, esketamine could offer a safer sedation option for septic patients on ventilators, potentially reducing delirium and improving outcomes.
What could go wrong: This is a small, single-center phase 4 trial with only 80 participants. Esketamine's benefits for this specific use are unproven, and side effects like hallucinations or blood pressure changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MECHANICAL VENTILATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MECHANICAL VENTILATION SEPSIS

Contacts and locations

Locations

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.